Recommended Source The BPC-157/TB-500 blend is available in 5 mg/5 mg combination vials from Heritage Labs USA, a U.S.-based research peptide supplier with batch-level purity verification
Gastrointestinal effects represent the most common concern: Nausea and vomiting : May be pronounced when initiating either medication or during Wegovy dose escalation Diarrhoea or constipation : Both medications can affect bowel habits Reduced appetite : Wegovy's appetite-suppressing effects combined with SSRI-related nausea may significantly reduce food intake Abdominal discomfort : Bloating, dyspepsia, or gastric pain may occur To minimise gastrointestinal distress, consider taking escitalopram with food and following the gradual Wegovy dose escalation schedule precisely
Instead of focusing on how treatment affects markers of glycemic control, which has not shown benefit, treatments should be based on anticipated reductions in cardiovascular and kidney disease outcomes
Boehringer Ingelheim Sanofi , ,
Knop FK, Aroda VR, Do Vale RD, et al
Pharmacol Rep